Your browser doesn't support javascript.
loading
The Clinical Outcomes and Toxicities of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.
Zou, Rui; Yuan, Jing-Jing; Li, Qiang; Ding, Jian-Wu; Liao, Bing; Tu, Zi-Wei; Hu, Rong-Huan; Gong, Dan; Hu, Jia-Li; Zeng, Lei.
Afiliação
  • Zou R; Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Yuan JJ; Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, China.
  • Li Q; Medical College of Nanchang University, Nanchang, China.
  • Ding JW; Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Liao B; Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, China.
  • Tu ZW; Medical College of Nanchang University, Nanchang, China.
  • Hu RH; Department of Lymphatic Hematologic Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, China.
  • Gong D; Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Hu JL; Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, China.
  • Zeng L; Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Front Oncol ; 10: 619625, 2020.
Article em En | MEDLINE | ID: mdl-33791194
PURPOSE: To analyze the outcomes and toxicities of induction chemotherapy (ICT) followed by concurrent chemoradiotherapy (CCRT) plus adjuvant chemotherapy (ACT) in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). METHODS: Retrospective analysis of 163 patients with LA-NPC referred from August 2015 to December 2018 was carried out. All patients underwent platinum-based ICT followed by CCRT plus ACT. RESULTS: The median follow-up time was 40 months, ranging from 5 to 69 months. The 3-year disease-free survival (DFS), overall survival (OS), locoregional recurrence-free survival (LRRFS), and distant metastasis-free survival (DMFS) rates were 80.8, 90.0, 91.6, and 87.4%, respectively. The most frequent acute grade 3/4 adverse events were leukopenia (66.8%), neutropenia (55.8%), mucositis (41.1%), thrombocytopenia (27.0%), and anemia (14.7%). CONCLUSION: ICT followed by CCRT plus ACT did not seemingly enhance DFS and OS in LA-NPC patients compared to the addition of ICT to CCRT (historical controls). In contrast, ICT followed by CCRT plus ACT had more acute adverse events than ICT followed by CCRT. Longer-term clinical studies are required to examine the treatment outcomes and late toxicities.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article